|
Valoración de DCF de Lyell Immunopharma, Inc. (Lyel)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Lyell Immunopharma, Inc. (LYEL) Bundle
¡Explore el potencial financiero de Lyell Immunopharma, Inc. (Lyel) con nuestra calculadora DCF fácil de usar! Ingrese sus proyecciones para el crecimiento, los márgenes y los gastos para determinar el valor intrínseco de Lyell Immunopharma, Inc. (Lyel) y refinar su enfoque de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .7 | 7.8 | 10.7 | 84.7 | .1 | .2 | .2 | .3 | .4 | .6 |
| Revenue Growth, % | 0 | 1080.52 | 37.31 | 695.15 | -99.85 | 34.37 | 34.37 | 34.37 | 34.37 | 34.37 |
| EBITDA | -100.8 | -207.6 | -199.9 | -166.7 | -226.8 | -.2 | -.2 | -.3 | -.4 | -.6 |
| EBITDA, % | -15347.49 | -2677.19 | -1877.39 | -196.79 | -174429.23 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 4.4 | 7.5 | 14.5 | 16.5 | 20.3 | .1 | .2 | .3 | .4 | .5 |
| Depreciation, % | 667.12 | 96.38 | 136.48 | 19.45 | 15576.92 | 83.16 | 83.16 | 83.16 | 83.16 | 83.16 |
| EBIT | -105.2 | -215.1 | -214.5 | -183.1 | -247.0 | -.2 | -.2 | -.3 | -.4 | -.6 |
| EBIT, % | -16014.61 | -2773.57 | -2013.87 | -216.24 | -190006.15 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 436.0 | 612.6 | 614.8 | 640.2 | 546.2 | .2 | .2 | .3 | .4 | .6 |
| Total Cash, percent | .1 | .0 | .0 | .0 | .4 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | 2.8 | 9.4 | 3.2 | 3.9 | 4.8 | .1 | .2 | .2 | .3 | .4 |
| Accounts Payable, % | 432.88 | 121.14 | 30.11 | 4.63 | 3705.38 | 66.95 | 66.95 | 66.95 | 66.95 | 66.95 |
| Capital Expenditure | -16.0 | -51.5 | -65.5 | -24.3 | -2.7 | -.1 | -.2 | -.3 | -.4 | -.5 |
| Capital Expenditure, % | -2442.47 | -663.76 | -615.06 | -28.67 | -2066.15 | -85.73 | -85.73 | -85.73 | -85.73 | -85.73 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -98.6 | -208.9 | -244.7 | -4.8 | -247.0 | -.1 | -.2 | -.2 | -.3 | -.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -107.4 | -246.3 | -301.9 | -11.9 | -228.5 | -4.8 | -.2 | -.2 | -.3 | -.4 |
| WACC, % | 5.05 | 5.09 | 5.13 | 3.92 | 5.13 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -13 | |||||||||
| Present Terminal Value | -10 | |||||||||
| Enterprise Value | -16 | |||||||||
| Net Debt | -82 | |||||||||
| Equity Value | 67 | |||||||||
| Diluted Shares Outstanding, MM | 251 | |||||||||
| Equity Value Per Share | 0.27 |
What You Will Get
- Real Lyell Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Lyell Immunopharma, Inc. (LYEL).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specifically for Lyell.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Lyell Immunopharma’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections related to Lyell Immunopharma, Inc. (LYEL).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for your Lyell analyses.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Lyell Immunopharma, Inc. (LYEL).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to LYEL.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit Lyell Immunopharma's projections.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Lyell Immunopharma, Inc. (LYEL).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Lyell Immunopharma data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Lyell Immunopharma’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Lyell Immunopharma, Inc. (LYEL)?
- Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses tailored for Lyell Immunopharma.
- Customizable Inputs: Modify yellow-highlighted cells to explore different investment scenarios.
- Detailed Insights: Automatically computes Lyell Immunopharma’s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focused on biotechnology.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for analyzing Lyell Immunopharma, Inc. (LYEL) within their portfolios.
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions regarding Lyell Immunopharma, Inc. (LYEL).
- Consultants and Advisors: Deliver precise valuation insights to clients interested in Lyell Immunopharma, Inc. (LYEL).
- Students and Educators: Utilize real-world data to learn and teach financial modeling with a focus on Lyell Immunopharma, Inc. (LYEL).
- Biotech Enthusiasts: Gain insights into how biotech firms like Lyell Immunopharma, Inc. (LYEL) are valued in the stock market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Lyell Immunopharma historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Lyell Immunopharma, Inc. (LYEL).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.